Inhibition of proteasome function has emerged as a powerful strategy for anti cancer therapy clinical validation of the proteasome as a therapeutic target was achieved with bortezomib and has prompted the development of a second generation of proteasome inhibitors with improved pharmacological properties. Authoritative and illuminating proteasome inhibitors in cancer therapy makes clear that proteasome inhibition should prove a fertile area for the many future discoveries that will provide relief of suffering and extend the quality of life of patients afflicted with cancer and other debilitating diseases. Proteasome inhibitors in cancer therapy edited by julian adams which is part of the cancer drug discovery and development series from humana press tells the happy tale of one drugs . The discovery of cisplatin a platinum based drug was a major breakthrough in cancer treatment strategies however the toxicity and drug resistance associated with cisplatin regulated the drug discovery research towards the rationale development of metal containing agents with more specific activity and less toxicity and mode of action different from cisplatin and its derivatives. Validation of the ubiquitin proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor bortezomib for relapsed refractory multiple myeloma and mantle cell lymphoma for which this agent has become a standard of care
How it works:
1. Register Trial Account.
2. Download The Books as you like ( Personal use )